Literature DB >> 2419491

Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies.

E E Walsh, P J Cote, B F Fernie, J J Schlesinger, M W Brandriss.   

Abstract

At least four distinct epitopes are described on the respiratory syncytial virus fusion protein (VP70) using 13 monoclonal antibodies in solid-phase competitive binding studies. Two, and possibly three, fusion-inhibiting epitopes, one non-fusion-inhibiting neutralizing epitope, and one non-neutralizing epitope are described. All but the latter site demonstrated partial overlap, suggesting possible topographical proximity of these epitopes. Polyclonal rabbit sera to VP70, which neutralized virus but did not inhibit fusion of infected cells, blocked the binding of all fusion-inhibiting monoclonal antibodies to VP70 in the solid-phase assay but did not inhibit their effect in vitro. Western blot analysis of these monoclonal antibodies demonstrates that one fusion-inhibiting epitope is localized on the 48K fragment of VP70 and is resistant to denaturation by heat, 2-mercaptoethanol and SDS.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2419491     DOI: 10.1099/0022-1317-67-3-505

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  17 in total

1.  Monoclonal antibodies to the fusion protein of bovine respiratory syncytial virus.

Authors:  K M Mulkey; G A Anderson
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

2.  Comparison of caprine, human and bovine strains of respiratory syncytial virus.

Authors:  M Trudel; F Nadon; C Simard; F Bélanger; R Alain; C Séguin; G Lussier
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

Review 3.  Immunity to human and bovine respiratory syncytial virus.

Authors:  T G Kimman; F Westenbrink
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

4.  Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function.

Authors:  J A Beeler; K van Wyke Coelingh
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

5.  Amino acid variation within the fusion protein of respiratory syncytial virus subtype A and B strains during annual epidemics in South Africa.

Authors:  Elizabeth Agenbach; Caroline T Tiemessen; Marietjie Venter
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

6.  Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.

Authors:  J S Kahn; A Roberts; C Weibel; L Buonocore; J K Rose
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Antigenic analysis of the F protein of the bovine respiratory syncytial virus: identification of two distinct antigenic sites involved in fusion inhibition.

Authors:  J P Matheise; K Walravens; A Collard; P Coppe; J J Letesson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

8.  Epitope specificities of human serum antibodies reactive with respiratory syncytial virus fusion protein.

Authors:  B S Robinson; J S Everson
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

9.  Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity.

Authors:  C F Barbas; J E Crowe; D Cababa; T M Jones; S L Zebedee; B R Murphy; R M Chanock; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres.

Authors:  Yoshihiko Murata; Paula M Lightfoote; Robert C Rose; Edward E Walsh
Journal:  Virol J       Date:  2009-06-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.